CN1314402C - Drug composition containing fructus tribuli fruit total saponin and its preparation method - Google Patents
Drug composition containing fructus tribuli fruit total saponin and its preparation method Download PDFInfo
- Publication number
- CN1314402C CN1314402C CN 02132482 CN02132482A CN1314402C CN 1314402 C CN1314402 C CN 1314402C CN 02132482 CN02132482 CN 02132482 CN 02132482 A CN02132482 A CN 02132482A CN 1314402 C CN1314402 C CN 1314402C
- Authority
- CN
- China
- Prior art keywords
- fructus tribuli
- alcohol
- total saponin
- fruit total
- tribuli fruit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Abstract
The present invention relates to a drug composition containing a Fructus Tribuli fruit total saponin and a preparation method thereof, particularly to an application of the Fructus Tribuli fruit total saponin in the prevention and the treatment of human or animal cardiac muscle and brain tissue ischemia and anoxia. The drug composition of the present invention contains more than 50%(w/w) of effective component in the Fructus Tribuli fruit total saponin, namely Fructus Tribuli furostanol saponin and Fructus Tribuli spirostane saponin, and one or a plurality of pharmaceutically acceptable carriers or excipients.
Description
Technical field:
The present invention relates to pharmaceutical composition that contains Fructus Tribuli fruit total saponin and preparation method thereof, particularly relate to the application of Fructus Tribuli fruit total saponin in prevention, treatment human or animal's cardiac muscle and cerebral tissue ischemia, anoxia.
Background technology:
Fructus Tribuli Tribulus terrestris L. belongs to zygophyllaceae plant Tribulus plant on Plant Taxonomy.Fructus Tribuli fruit and stem and leaf all contain many kinds of steroidal saponins, and the saponin constituent to Fructus Tribuli had carried out some researchs in recent years, find that total saponins of tribulus has wide biological activity.
Early sixties, people such as Nag. and Tombesi have successively isolated diosgenin (Diosgenin) and hecogenin and 3-deoxidation diosgenin-3-deo-xy-Δ 33-diosgenin. from the Fructus Tribuli fruit.People such as wang yan isolated terrestrosin A from the Fructus Tribuli fruit in 1996, and D waits 10 spirostanol saponins and terrestrosinH, G, 6 furostanol monomeric compounds such as I.But so far still not about Fructus Tribuli fruit total saponin being developed to the report of medicine.
Summary of the invention:
The object of the present invention is to provide a class new to have the medicinal compositions with Fructus Tribuli fruit total saponin be the primary activity composition.
It is the method for the pharmaceutical composition of primary activity composition with the Fructus Tribuli fruit total saponin that another object of the present invention provides production.
Further purpose of the present invention provides a kind of pharmaceutical composition that cardiac muscle that the sclerosis of heart, cerebral artery vessel or thromboembolism cause and cerebral tissue ischemia, anoxia and lipid oxide raise for the treatment of.
Another object of the present invention provides the application that a kind of compositions with Fructus Tribuli fruit total saponin is the medicine aspect that raises of the cardiac muscle that causes of primary activity composition preparation treatment heart, cerebral artery vessel sclerosis or thromboembolism and cerebral tissue ischemia, anoxia and lipid oxide.
Primary activity composition in the Fructus Tribuli fruit total saponin of the present invention is made up of spirostanol saponin and furostanol.Its preparation technology is:
A, get raw material Fructus Tribuli fruit, with 0%-95% alcohol extraction 1-10 time, preferably use 70% alcohol extraction, extracts 3 times, extracting solution merges, filtration, and filtrate process macroporous adsorptive resins can be AB-8; B, wash with water after colourless, best with collecting eluent behind the 40%-95% alcohol eluting with 60% pure eluting, reclaim alcohol, to there not being the alcohol flavor, be not condensed into extractum shape or dry powder under the decompression or under the normal pressure; C, with 60%-95% alcohol dissolving, the most handy 80% alcohol dissolving filters, disgorging also reclaims filtrate, obtains required Fructus Tribuli fruit total saponin behind the reclaim under reduced pressure alcohol.Chemical analysis shows that Radix Panacis Quinquefolii stem and leaf total saponins content is approximately more than 50% in the gained end-product.
Its preparation of drug combination method may further comprise the steps:
(1) provides Fructus Tribuli fruit total saponin;
(2) step (1) being obtained Fructus Tribuli total saponins mixes mutually with one or more pharmaceutically acceptable carriers and/or excipient.
Pharmaceutical composition of the present invention contains effective ingredient puncturevine furostanol saponins in the Fructus Tribuli fruit total saponin and the content of Fructus Tribuli spirostanol saponin is more than 50% (w/w), and contains the pharmaceutical composition of one or more pharmaceutically acceptable carriers or excipient.
The present invention has therapeutical effect aspect the cardiac muscle that causes at the sclerosis of heart, cerebral artery vessel or thromboembolism of the drug regimen of primary activity composition and cerebral tissue ischemia, anoxia and the lipid oxide rising.
A large amount of general pharmacologies is learned and pharmacodynamic experiment shows; Pharmaceutical composition of the present invention is to activity and the not obviously influence of behavior of animal (mice, rat and dog).With 200mg/kg and 100mg/kg continuous irrigation stomach three days, the fruit Fructus Tribuli total saponins was administered once through duodenal intubation with 30mg/kg Fructus Tribuli fruit total saponin respectively, and the blood pressure of animal, heart rate and electrocardiogram are all normal substantially, find no significant variation on the statistics.The pharmacodynamic study result shows, pharmaceutical composition of the present invention (50-100mg/kg) duodenal administration can reduce to block the focal cerebral ischemia in rats area due to the middle cerebral artery (MCAO); The cerebrovascular permeability that suppresses acute imperfection cerebral ischemic model rat raises, and stops the formation of cerebral edema; High-caliber thromboxane A after the reduction cerebral ischemia
2(TXA
2), but to prostacyclin (PGI
2) then there is not influence, thus PGI changed
2/ TXA
2Ratio, suppress thrombus in vivo formation; Reduce content of ET in the rats with cerebral ischemia blood, improve superoxide dismutase activity in the blood; Reduce the blood viscosity of blood stasis model rat, anticoagulant; Improve rheological property of blood; (200mg/kg) gastric infusion also can promote fibrinolysis; Improve mice normal pressure hypoxia-bearing capability.In addition, (15-30mg/kg) duodenal administration can increase the cerebral blood flow of anesthetized dog, reduces cerebral vascular resistance, makes the decreased heart rate of dog, blood pressure drops.Therefore, Fructus Tribuli fruit total saponin has significant protective effect to experimental cerebral ischemia.
In addition, what should particularly point out is, can add one or more natural or synthetic other as required and have the active component of collaborative or assosting effect with Fructus Tribuli fruit total saponin in pharmaceutical composition of the present invention. the natural or synthetic auxiliary activity composition that these may be added into be well known by persons skilled in the art with can expect.
Pharmaceutically acceptable carrier of Fructus Tribuli fruit total saponin and one or more or excipient can be mixed by proper proportion, make the suitable son pharmaceutical composition of the different dosage form of use clinically. for example said compositions can be mixed with and can supply intravenous, the injection of intramuscular, intraperitoneal, subcutaneous, marrowbrain intracavity and the inner injecting and administering of shouting is perhaps made the tablet, the powder agent that are suitable for oral administration.Pill, capsule and suspending agent, and the spray, cream, ointment and the suppository that are suitable for topical.
In order to prepare the solution that is suitable for the outer approach medicine of gastrointestinal tract, for example can use distilled water, water for injection, isotonic sodium chlorrde solution or glucose solution, perhaps low concentration (for example 1-100mM) phosphate buffered saline (PBS) (PBS) is as carrier or excipient.Can in the preparation of these gastrointestinal tract external administrations, add one or more other auxiliary elements or additives, for example can use ascorbic acid as antioxidant, use sodium benzoate or Metagin cheese as antiseptic, use dimethyl sulfoxide as absorption enhancer.
In order to prepare tablet, the powder agent that is suitable for oral administration, suspending agent or capsule can use sucrose, galactose, corn starch, gelatin, lipid, microcrystalline Cellulose, Pulvis Talci etc. as carrier or excipient.Be suitable for also can containing other proper additive in the preparation of oral administration for example solubilizing agent, disintegrating agent, lubricant, absorption enhancer, dispersant, surfactant, flavor flavor agent or coloring agent etc. at these.
Preferably pharmaceutical composition of the present invention is made the various oral dosage forms of cheating medicine that are suitable for, for example tablet, powder agent, capsule, or oral liquid or Emulsion. the unit dose of these oral formulations generally comprises the 30-200mg Fructus Tribuli fruit total saponin.When for example being used for the treatment of the ischemic cardio-cerebral diseases, the adult dosage of common 60 kg body weight is 50-600mg every day, divides three administrations.Another preferred route of administering of pharmaceutical composition of the present invention is the injection that intravenous or intramuscular injection are suitable for these route of administration.For example for some acute myocardial infarction or cerebral embolism acute stage or convalescent patient, or the patient of the frequent outbreak of angina pectoris, the injection formulation of pharmaceutical composition of the present invention can be added in etc. and ooze in glucose solution or the isotonic sodium chlorrde solution, constantly dropleting medicine-feeding.The dosage of intravenous administration is generally 50-200mg every day.
The present invention further provides the said application of pharmaceutical composition in treatment or prevention whole body or local organization, particularly heart and brain tissues ischemia, anoxia and related pathologies condition that contains Fructus Tribuli fruit total saponin.
The specific embodiment:
Below in conjunction with embodiment the present invention is further described:
Embodiment 1: the preparation of Fructus Tribuli fruit total saponin
In container, will clean in advance and exsiccant Fructus Tribuli fruit 1000g adds an amount of water heated and boiled (three times repeatedly, each 60 minutes). collect and merge the flooding extract of gained, and filter, filtrate is added in advance on the large aperture adsorption resin AB-8 that handles with bronsted lowry acids and bases bronsted lowry (the Chinese Tianjin Nankai University chemistry) post, with deionized water wash post after eluate does not have color with 65% ethanol (about 500ml) eluting.Collecting refluxes under effusive eluate and the son decompression concentrates it, and the gained concentrate is placed MgSO in the empty true exsiccator
4Obtain the total Saponin 18g of yellow powder shape (yield 1.8%) after the drying of top.
Embodiment 2: the component analysis of Fructus Tribuli fruit total saponin
To be dissolved in the 1000ml distilled water by the Fructus Tribuli fruit total saponin 25.0g that the described method of embodiment 1 is extracted, extract 5 times (each 100mi) repeatedly with ethyl acetate and collect and merge resulting acetic acid ethyl acetate extract, carry out silica gel column chromatography, use CHCl
3-MeOH gradient elution merges identical flow point, gets A from 39-62, gets B from 63-81, gets C from 82-112.B carries out silica gel column chromatography, with CHCl
3-EtOH solvent system gradient elution, every part is 100ml, gets Compound I (86mg) from 13-32 part, A separates through silica gel once more, with CHCl
3(9: 1-8: 2) eluting, every 100ml are 1 part to-EtOH, get a mixture in 21-34 part.This mixture separates through preparation HPLC, uses 60%, 50% successively, and 40%MeOH aqueous solution eluting gets Compound I I (72mg).
Compound I: white powder, mp 273-275 ℃ (MeOH), IR (KBr) cm
-13420,2930,2874,1706,1654,1631,1453,1429,1375,1243,1228,1159,1070,986,920,898,851,772,669.ES1/Ms m/z 915.1 (M
+-1)
-, 939.7 (M
++ Na)
+, 777.1 (M
++ Na-162)
+, 753.1 (M
+-H-162)
-, 615.1 (M
++ Na-162-162)
+, 591.3 (M
+-H-162-162)
-.
1HNMR (δ, C
5D
5N): 0.65 (3H, s, 19-Me), 1.07 (3H, s, 18-Me), 1.06 (3H, d, J=6.5Hz, 27-Me), 1.34 (3H, d, J=6.5Hz, 21-Me), 4.87 (1H, d, J=7.5Hz, Gal 1-H), 5.14 (1H, d, J=7.5Hz, Glc (2) 1-H), 5.22 (1H, d, J=7.2Hz, Glc (1) 1-H). through IH-NRR and ' 3C-NMR spectrum analysis result confirms that I is new steroidal saponin, called after total saponins of tribulus A.
Compound I I: 263-265 ℃ of IR of white powder mp (KBr) cm
-13423,1708,1632,1454,1373,987,919,898,856.MALDI/MS m/z 793 (M+K)
+, 777 (M
++ Na)
+.
1HNMR (δ, C
5D
5N), 0.70 (3H, s, 19-Me), 1.02 (3H, s, 18-Me), 1.08 (3H, d, J=6.8Hz, 27-Me), 1.34 (3H, d, J=6.8Hz, 21-Me), 4.60 (1H, d, J=7.5Hz, Gal 1-H), 5.11 (1H, d, J=7.5Hz, Glc 1-H). through IH-NRR and ' 3C-NMR spectrum analysis result confirms that Compound I I is a noval chemical compound, called after total saponins of tribulus B respectively.
Embodiment 3: Fructus Tribuli fruit total saponin is to the influence of rat thrombus in vivo
Be to be the Wistar rat that influence body weight 300-400g of the pharmaceutical composition (hereinafter to be referred as western Fructus Tribuli fruit total saponin compositions) of primary activity composition with the Fructus Tribuli fruit total saponin to the rat thrombus in vivo, press table 5 grouping administration, once a day, continuous irrigation stomach three days, last administration 30min lumbar injection chloral hydrate (360mg/kg) anesthesia, right carotid and left side external jugular vein are fixed and isolated to dorsal position, put into one in the stage casing of polyethylene tube and weigh in advance and be about No. 4 surgical threads of 6cm, (50u/ml) is full of the polyethylene tube chamber with heparin-saline solution.After an end of pipe inserted left external jugular vein, the other end injected heparin (50u/kg) anticoagulant exactly, and then inserted right common carotid artery.Blood flow in the polyethylene tube from right common carotid artery, backflows into left external jugular vein again, and blocking blood flow behind the 15min takes out silk thread rapidly and weighs, and gross weight deducts the line amount and promptly gets wet weight of thrombus, the results are shown in Table 5.Found that, Fructus Tribuli fruit total saponin 50 and 100mg/kg, Xinnao Shutong 100mg/kg can obviously suppress thrombosis, and 25mg/kg is invalid.
Embodiment 4: Fructus Tribuli fruit total saponin to cerebral ischemia after brain water content and capillary permeability influence body weight 250-300gWistar male rat, the anesthesia of 3.5% chloral hydrate lumbar injection (360mg/Kg), the blue 60mg/Kg of tail vein injection ivens behind separation vagus nerve and the common carotid artery, the vagal common carotid artery of ligation band behind the 10min, promptly be engraved in abdominal part after the ligation and cut an osculum, be subjected to reagent thing (model group, sham operated rats give the equivalent normal saline) through duodenum, put back to cage behind the layer-by-layer suture wound and raise.Broken end is got brain behind the 5h, is that sign cuts in half brain with the longitudinal fissure, gets right half brain and surveys brain water content by dried wet method; After getting left half brain and weighing, put in the formamide solution, survey trap at 632nm place with spectrophotometer behind 45 ℃ of following incubation 60h, the content according to ivens orchid in the standard curve calculating brain the results are shown in Table 2.The result shows Fructus Tribuli fruit total saponin 50 and 100mg/kg, and the blue content of ivens obviously descends in Xinnao Shutong 100mg/kg dosage group and brain water content after the ischemia model group is compared cerebral ischemia and the brain, and the cerebral edema of alleviating effect is arranged.
Embodiment 5: Fructus Tribuli fruit total saponin is to SOD, Endothelin, 6-Keto-PGF in the cerebral ischemia bleeding from anus
1 αAnd TXB
2The operation that influences rats underwent blocking-up middle cerebral artery after administration, get blood (get 10 μ l simultaneously and add the mensuration that is used for SOD behind the abundant haemolysis of 2.0ml distilled water) behind the 24h, a part places and contains 10%Na
2In the test tube of-EDTA30 μ l and 400u aprotinin (mensuration that is used for Endothelin), another part places and contains indometacin-Na
2(be used for 6-Keto-PGF in the test tube of EDTA100ul
1 αAnd TXB
2Mensuration), the centrifugal 10min of 3000r/min separates preparation blood plasma, press the operation of test kit description, mensuration SOD, Endothelin, 6-Keto-PGF
1 αAnd TXB
2The results are shown in Table 3 and table 4, the result shows Fructus Tribuli fruit total saponin 50 and 100mg/kg, and Xinnao Shutong 100mg/kg dosage group compares with the ischemia model group that SOD obviously raises in the cerebral ischemia bleeding from anus, and content of ET obviously reduces (P＜0.05); 6-Keto-PGF
1 αNo significant change, but TXB
2Level obviously reduces (P＜0.05), thereby makes PGI
2/ TXA
2Ratio increases, and reduces the thrombosis probability.
Embodiment 6.
Fructus Tribuli fruit total saponin is to the Wistar rat that influences body weight 200-300g of blood stasis model rat blood rheological characteristic, press table 8 grouping administration, every day, gastric infusion one, continuous 7 days, hemopoietic stasis of blood model after the last administration: the adrenalin hydrochloride 0.8ml/kg of subcutaneous injection 10 μ g/ml, twice totally, interval 4h, and during this period rat is immersed 5min in the frozen water, water is can't help in fasting then, animal lumbar injection chloral hydrate in morning next day (360mg/kg) anesthesia, abdominal aortic blood, survey whole blood and blood plasma specific viscosity, the results are shown in Table 8.The visible Fructus Tribuli fruit total saponin 50-100mg/kg of result, Xinnao Shutong 100mg/kg can obviously reduce whole blood and blood plasma viscosity.
The influence that table 1 Fructus Tribuli fruit total saponin forms rat suppository (X ± SD, n=10)
| Group | Dosage (mg/Kg) | Thrombosis heavy (mg) | Suppression ratio % |
| Matched group Xinnao Shutong total saponins group | 100 25 50 100 | 30.2±6.4 22.4±4.7 ** 27.8±7.6 23.7±6.0 * 20.6±5.4 ** | - 25.83 7.95 21.52 31.79 |
Compare with matched group
*P＜0.05;
*P＜0.01
Table 2. Fructus Tribuli fruit total saponin to rat cerebral ischemia after brain water content and vascular permeability influence (X ± SD, n=10)
| Group | Dosage (mg/Kg) | Brain water content (%) | The blue content of ivens (the ug/g cutaneous horn is heavy) in the cerebral tissue |
| Sham operated rats membranous type group Xinnao Shutong total saponins group | --- --- 100 25 50 100 | 78.35±0.80 79.43±0.91 78.40±1.09 * 78.83±0.79 78.52±0.71 * 78.70±0.65 * | 1.95±0.47 3.76±1.47 2.56±0.65 * 3.10±0.72 2.57±0.63 * 2.36±0.61 * |
Compare with the membranous type group
*P＜0.05;
*P＜0.01
Table 3. Fructus Tribuli fruit total saponin to the influence of content of ET in the rat cerebral ischemia bleeding from anus and SOD content (X ± SD, n=10)
| Group | Dosage (mg/Kg) | Content of ET (ng/L) | SOD content (ng/L) |
| Sham operated rats model group Xinnao Shutong total saponins group | --- --- 100 25 50 100 | 226.4±109.2 421.3±148.1 281.4±106.8 * 339.5±117.6 284.7±103.9 * 272.6±105.7 * | 13.30±3.27 9.65±2.32 13.18±3.93 * 11.02±2.75 12.15±2.01 * 13.02±3.42 * |
Compare with model group
*P＜0.05;
*P＜0.01
Table 4. Fructus Tribuli fruit total saponin is to 6-Keto-PGF in the cerebral ischemia bleeding from anus
1 αAnd TXB
2Influence (X ± SD, n=10)
| Group | Dosage (mg/Kg) | 6-Keto-PGF 1α(ng/L) | TXB 2(ng/L) |
| Sham operated rats model group Xinnao Shutong total saponins group | 100 25 50 100 | 522.9±209.1 628.9±317.9 563.0±255.0 660.8±289.1 559.3±296.9 595.9±288.4 | 230.5±163.4 507.8±182.8 326.5±157.8 * 389.6±129.5 343.3±161.4 * 309.0±179.1 * |
Compare with model group
*P＜0.05;
*P＜0.01
Table 5 Fructus Tribuli fruit total saponin to the influence of blood stasis hemorheology of rat (X ± SD, n=10)
| Dosage (mg/ug) | Whole blood viscosity | Plasma viscosity | |||
| Low cutting | In cut | Height is cut | |||
| Blank model group Xinnao Shutong total saponins group | -- 100 25 50 100 | 14.74±2.41 18.59±1.06 14.92±3.65 ** 17.04±2.34 15.74±3.91 * 15.05±2.88 ** | 8.43±1.13 10.21±0.86 8.51±1.64 ** 9.74±1.70 8.85±2.14 8.99±1.36 * | 5.73±0.67 7.68±0.72 5.85±0.98 ** 7.04±1.04 6.37±1.67 * 6.24±1.18 ** | 1.72±0.22 2.10±0.21 1.83±0.28 * 1.90±0.21 * 1.97±0.38 1.80±0.20 ** |
Compare with model group:
*P＜0.05
*P＞0.01
Claims (2)
1, the pharmaceutical composition that raises of the cardiac muscle that causes of a kind of treatment heart that contains Fructus Tribuli fruit total saponin, cerebral artery vessel sclerosis or thromboembolism and cerebral tissue ischemia, anoxia and lipid oxide, it is characterized in that: the effective ingredient puncturevine furostanol saponins in the described Fructus Tribuli fruit total saponin and the content of Fructus Tribuli spirostanol saponin are more than 50% weight ratio, and contain the pharmaceutical composition of one or more pharmaceutically acceptable carriers or excipient;
Described Fructus Tribuli fruit total saponin is obtained by following method: get raw material Fructus Tribuli fruit, with 0%-95% alcohol extraction 1-10 time, extracting solution merges, filter, filtrate is through the AB-8 macroporous adsorptive resins, washes with water after colourless, with collecting eluent behind the 60%-95% alcohol eluting, reclaim alcohol, to there not being the alcohol flavor, decompression is condensed into extractum shape or dry powder down or under the normal pressure; With the alcohol dissolving, filter, disgorging also reclaims filtrate, obtains required Fructus Tribuli fruit total Saponin behind the reclaim under reduced pressure alcohol.
2, a kind of preparation method of Fructus Tribuli fruit total saponin, make by following steps: get raw material Fructus Tribuli fruit, with 0%-95% alcohol extraction 1-10 time, extracting solution merges, and filters, filtrate is through the AB-8 macroporous adsorptive resins, wash with water after colourless,, reclaim alcohol with collecting eluent behind the 60%-95% alcohol eluting, to there not being the alcohol flavor, decompression is condensed into extractum shape or dry powder down or under the normal pressure; With the alcohol dissolving, filter, disgorging also reclaims filtrate, obtains required Fructus Tribuli fruit total Saponin behind the reclaim under reduced pressure alcohol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02132482 CN1314402C (en) | 2002-06-27 | 2002-06-27 | Drug composition containing fructus tribuli fruit total saponin and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02132482 CN1314402C (en) | 2002-06-27 | 2002-06-27 | Drug composition containing fructus tribuli fruit total saponin and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1413588A CN1413588A (en) | 2003-04-30 |
| CN1314402C true CN1314402C (en) | 2007-05-09 |
Family
ID=4746796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02132482 Expired - Fee Related CN1314402C (en) | 2002-06-27 | 2002-06-27 | Drug composition containing fructus tribuli fruit total saponin and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1314402C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100457130C (en) * | 2004-12-17 | 2009-02-04 | 吉林敖东洮南药业股份有限公司 | Refined puncturevine fruit saponin capable of being administered by injection, its preparing process and injecta |
| CN101019905B (en) * | 2007-02-13 | 2013-01-09 | 南京艾德凯腾生物医药有限责任公司 | Medicine composition containing tribulus fruit furostanol saponin and application thereof |
| CN101953868B (en) * | 2010-09-15 | 2011-08-17 | 吉林敖东洮南药业股份有限公司 | Detection method for total saponins of tribulus |
| CN105311067A (en) * | 2014-07-29 | 2016-02-10 | 西安旭煌生物技术有限公司 | Method for extracting total tribulus terrestris saponins from stems and leaves of tribulus terrestris |
| CN104474150B (en) * | 2014-11-26 | 2018-02-16 | 烟台市华昕生物医药科技有限公司 | A kind of pharmaceutical composition and preparation method with oxygen lack resistant function |
-
2002
- 2002-06-27 CN CN 02132482 patent/CN1314402C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1413588A (en) | 2003-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070111955A1 (en) | Extraction and purification method of active constituents from stem of Lonicera japonica Thunb., its usage for anti-inflammatory and analgesic drug | |
| CN101775058B (en) | Preparation and application of pharmaceutical preparation of 11-carbonyl-betal- acetyl mastic acid and derivatives thereof extracted from frankincense | |
| WO2018133563A1 (en) | Panax plant extract and pharmaceutical composition and use thereof | |
| KR20040074614A (en) | Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa(schenk.)wight, process of making the same, and uses of the same | |
| EP2172206A1 (en) | The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof | |
| CN1314402C (en) | Drug composition containing fructus tribuli fruit total saponin and its preparation method | |
| CN112047954B (en) | Iridoid compound and preparation method and application thereof | |
| CN100467025C (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| TW201424746A (en) | Alpinia spp. extracts for treating irritable bowel syndrome | |
| CN1698717B (en) | Chinese medicinal compound fat emulsion injection and its preparation method | |
| CN112891362B (en) | Pharmaceutical composition for treating sepsis and application thereof | |
| JP2004521075A (en) | Bioactive fraction of Eurycomalongifolia | |
| US6475520B1 (en) | Pharmaceutical composition with low toxicity for anti-inflammation and anti-exudation | |
| CN103417597A (en) | Rape pollen total phytosterol effective part as well as preparation method and application thereof | |
| KR100195884B1 (en) | Blood glucose lowering composition containing extract of astragali radix and process for preparing extract of astragali radix | |
| KR102279105B1 (en) | Composition for preventing or treating renal disease comprising Zizyphus jujuba MILL extract | |
| BRPI0617264A2 (en) | pharmaceutical composition useful as a leishmanicidal agent | |
| CN114394931B (en) | Monoterpene alkaloid with vasodilation activity and extraction method and application thereof | |
| CN114409544B (en) | Phenylpropanoid with vasodilation activity, and extraction method and application thereof | |
| WO2011147754A1 (en) | Method for producing an enriched extract from vitis vinifera l. leaves | |
| EP1498131A1 (en) | Medicinal preparation containing phenylethanoid glycosides extracted from Cistanche tubulosa | |
| US3950518A (en) | Hypoglycemic composition and method of use | |
| KR100202757B1 (en) | Anti-diabetic composition | |
| JPH0535131B2 (en) | ||
| JPH0717507B2 (en) | Antithrombotic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070509 Termination date: 20170627 |